-Reuters
Related Posts
Keybanc Maintains Overweight on Agilent Technologies, Raises Price Target to $195
Keybanc analyst Paul Knight maintains Agilent Technologies (NYSE:A) with a Overweight and raises the price target from $160 to $195.
Fennec Pharmaceuticals Resubmits New Drug Application To FDA For Pedmark
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.